Key facts
- Sidewinder Therapeutics’s last known valuation is $204.0M (Mar 2026).
- It has raised $161.0M; the latest was Early Stage VC ($137.0M) in Mar 2026.
- Notable investors include Alexandria Venture Investments, OrbiMed, Goldman Sachs Asset Management, Samsara BioCapital, Frazier Healthcare Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Sidewinder Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sidewinder Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sidewinder Therapeutics
Operator of a precision biologics development company intended to deliver new life-saving therapies for cancer and rare disease patients. The company offers medicines that target specific molecular drivers of disease, enabling customers to access new life-saving therapies for cancer and rare diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 7
- Website
- sidewinderbio.com/
- Ownership
- Privately Held (backing)
Sidewinder Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sidewinder Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sidewinder Therapeutics in its N-PORT filings yet. We sweep new filings monthly.